---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-22-000081"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T14:47:11.586747+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allogene reports Q3 net loss of $83.1M; initiates first allogeneic CAR T Phase 2 trial

## Summary
- Net loss $83.1M ($0.58/share); R&D expenses $63.6M; G&A $18.9M.
- Cash & investments $637M at Sep 30; 2022 cash burn guidance <$250M.
- Initiated ALPHA2 Phase 2 trial of ALLO-501A in relapsed/refractory large B-cell lymphoma.
- R&D Showcase on Nov 29, 2022 to feature updated CD19 and BCMA data.
- FY 2022 GAAP operating expenses slightly below prior $360M-$390M guidance.

## SEC filing metadata
- accession: 0001737287-22-000081
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000081/0001737287-22-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000081/allo-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-22-000081
- JSON: https://secwatch.observer/filing/0001737287-22-000081.json
- Plain text: https://secwatch.observer/filing/0001737287-22-000081.txt

## Key facts
- Earnings Releases
  Allogene Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $83.1 million, EPS $0.58 per share.
  - Period: the quarter ended September 30, 2022
  - Net income: $83.1 million
  - EPS: $0.58 per share
  - Result: reported results
  source text: Net loss for the third quarter of 2022 was $83.1 million, or $0.58 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000081/0001737287-22-000081-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.